- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:patients:protocol_overview [07.03.2017] – [Introduction to the Marshall Protocol] sallieq | home:patients:protocol_overview [05.26.2019] – sallieq | ||
|---|---|---|---|
| Line 8: | Line 8: | ||
| At its essence, the MP involves five key elements, each of which is supported by the [[home: | At its essence, the MP involves five key elements, each of which is supported by the [[home: | ||
| - | * take a minimum of four doses of olmesartan (Benicar) per day | + | * take a minimum of four X 40mg doses of olmesartan (Benicar) per day |
| * wean off any immunosuppressive or potentially immunosuppressive [[home: | * wean off any immunosuppressive or potentially immunosuppressive [[home: | ||
| * avoid the consumption of vitamin D, as well as certain other immunosuppressive [[home: | * avoid the consumption of vitamin D, as well as certain other immunosuppressive [[home: | ||
| Line 24: | Line 24: | ||
| ===== Medications used ===== | ===== Medications used ===== | ||
| + | |||
| + | The document [[home: | ||
| + | |||
| + | Without active participation of patients on MarshallProtocol.com site, Autoimmunity Research Foundation does not support or license the public use of this therapy. | ||
| - | {{section>: | ||
| Line 85: | Line 88: | ||
| * [[home: | * [[home: | ||
| * [[home: | * [[home: | ||
| + | * [[home: | ||
| - | + | {{tag> | |
| - | {{tag>Simple_Explanations}} | + | |
| - | + | ||
| Line 96: | Line 97: | ||
| + | {{tag> | ||
| * Legacy content | * Legacy content | ||
home/patients/protocol_overview.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.